Kanouse Andrew, Sohail Rubab, Salemi Parissa
Division of Diabetes and Endocrinology, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, NY 11042, USA.
Biostatistics Unit, Office of Academic Affairs, Northwell Health, New Hyde Park, NY 11040, USA.
J Endocr Soc. 2025 Sep 15;9(10):bvaf142. doi: 10.1210/jendso/bvaf142. eCollection 2025 Oct.
Children with diabetes mellitus (DM) have an increased risk for cardiovascular disease (CVD), a risk potentially exacerbated by elevated lipoprotein(a) (Lp(a)). While other cholesterol parameters are screened in this population, Lp(a) is often overlooked despite being an independent CVD risk factor. Lp(a) levels are historically believed to not change over an individual's life and are genetically determined, but newer literature suggests variation.
This study investigated Lp(a) levels and their relationship with glycated hemoglobin A (HbA) in children with incident diabetes mellitus (DM).
Children and adolescents aged 5 to 18 years with incident DM had baseline Lp(a) and lipid profiles. Repeat Lp(a) and HbA were obtained 3 months later. Descriptive statistics (frequencies, proportions, means, medians) and nonparametric tests (Spearman correlation, Wilcoxon rank-sum/Kruskal-Wallis) were used. Statistical significance was set at less than .05.
Seventy-six children were included for evaluation: 76% with type 1% and 23% type 2 DM. Baseline median (Q1-Q3) Lp(a) was 43.3 nmol/L (13-73.7 nmol/L), 17 of which were elevated (≥75 nmol/L). Of the 22 participants with follow-up, 8 were abnormal: A total of 4 whose baseline Lp(a) were abnormal remained so and 4 with normal levels became abnormal. A positive correlation was found between 3-month Lp(a) values and HbA ( = .004).
Children with DM have abnormal Lp(a) levels at a prevalence of approximately 20%, so this should be considered in CVD risk stratification. Further, observed Lp(a) fluctuations suggest value in serial Lp(a) assessments due to nongenetic influences. Without Lp(a) quantification, CVD risk characterization in children with DM may be inaccurate and should be considered for a comprehensive assessment.
糖尿病(DM)患儿患心血管疾病(CVD)的风险增加,脂蛋白(a)[Lp(a)]升高可能会加剧这种风险。虽然该人群会筛查其他胆固醇参数,但Lp(a)尽管是独立的CVD危险因素,却常常被忽视。从历史上看,人们认为Lp(a)水平在个体一生中不会改变,且由基因决定,但最新文献表明存在差异。
本研究调查了初发糖尿病(DM)患儿的Lp(a)水平及其与糖化血红蛋白A(HbA)的关系。
5至18岁初发DM的儿童和青少年进行了基线Lp(a)和血脂谱检查。3个月后重复检测Lp(a)和HbA。使用描述性统计(频率、比例、均值、中位数)和非参数检验(Spearman相关性、Wilcoxon秩和/Kruskal-Wallis检验)。设定统计学显著性水平为小于0.05。
纳入76名儿童进行评估:76%为1型糖尿病,23%为2型糖尿病。基线Lp(a)中位数(Q1-Q3)为43.3 nmol/L(13-73.7 nmol/L),其中17例升高(≥75 nmol/L)。在22名有随访的参与者中,8例异常:共有4例基线Lp(a)异常者仍保持异常,4例正常者变为异常。发现3个月时的Lp(a)值与HbA之间存在正相关(P = 0.004)。
DM患儿中Lp(a)水平异常的患病率约为20%,因此在CVD风险分层中应予以考虑。此外,观察到的Lp(a)波动表明,由于非遗传因素的影响,连续Lp(a)评估具有价值。如果不进行Lp(a)定量,DM患儿的CVD风险特征可能不准确,应考虑进行全面评估。